Non-small cell lung cancer: Afatinib provides more than one year additional survival in patients with the most common type of EGFR mutation ( del19 ) compared to chemotherapy
Boehringer Ingelheim has announced results of the pre-specified individual, as well as the exploratory combined, analyses of two phase III trials ( LUX-Lung 3 and LUX-Lung 6 ). These data have demonstrated for the first time that patients with non-small-cell lung carcinoma ( NSCLC ) with the most common epidermal growth factor receptor ( EGFR ) mutation ( exon 19 deletions; del19 ) lived more than one year longer if treated with first-line Afatinib ( Giotrif ) compared to chemotherapy.
Del19 is the most common type of EGFR mutation. It accounts for 50% of all EGFR mutations. The prevalence of EGFR mutations is approximately 40% among Asian patients and 10-15% among Caucasian patients with lung adenocarcinoma.
For patients with the del19 mutation Afatinib has prolonged survival by 12.2 months versus chemotherapy in the LUX-Lung 3 trial, and 13.0 months versus chemotherapy in the LUX-Lung 6 trial. ( Xagena )
Source: Boehringer-Ingelheim, 2014